# ABT-510 in Treating Patients With Metastatic Melanoma

> **NCT00602199** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 42 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** ABT-510
- **OTHER:** immunoenzyme technique
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00602199
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2011-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602199, "ABT-510 in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00602199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*